Overview

Evaluate the Safety and Pharmacokinetics of Ricolinostat

Status:
Not yet recruiting
Trial end date:
2022-06-12
Target enrollment:
Participant gender:
Summary
This study is an open-label, phase I clinical study to evaluate the safety and pharmacokinetics of ricolinostat in healthy Chinese adult subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Beijing 3E-Regenacy Pharmaceuticals Co., Ltd.
Treatments:
Ricolinostat